Hope S. Rugo, MD

Articles

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

Novel Chemoprotective Therapies Under Investigation

November 29th 2021

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

CIN: Takeaways From the PROTECTIVE-1 Study

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

CIN Treatment Advances: SIMBA Therapy

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

Dr. Rugo on Overall Survival With First-Line Pembrolizumab in Metastatic TNBC

September 19th 2021

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

May 21st 2020

Hope S. Rugo, MD, discusses the results of the phase 3 KEYNOTE-522 trial in triple-negative breast cancer (TNBC).

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

May 14th 2020

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

May 13th 2020

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Dr. Rugo on the Utility of Margetuximab in HER2+ Metastatic Breast Cancer

March 11th 2020

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Dr. Rugo on the Impact of Margetuximab Based on CD16A Fc Receptors in HER2+ Breast Cancer

January 14th 2020

Hope S. Rugo, MD, discusses the impact of margetuximab in patients with HER2-positive metastatic breast cancer who have an F allele versus V allele.

Dr. Rugo on Findings of Oral Paclitaxel With Encequidar in Metastatic Breast Cancer

January 8th 2020

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer

December 14th 2019

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast Cancer

October 31st 2019

Hope S. Rugo, MD, discusses the rationale for the phase II ELAINE study with lasofoxifene in patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Rugo on Unmet Needs Beyond Second-Line Treatment in HER2+ Breast Cancer

June 21st 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses unmet needs beyond second-line treatment in HER2+ breast cancer.

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer

June 4th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Dr. Rugo Discusses Regulatory Process Behind Biosimilars

April 3rd 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the regulatory process behind biosimilars in oncology.

NEXT PAGE
PREVIOUS PAGE